IOVA

The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could potentially beat their upcoming earnings reports. Idexx Laboratories (IDXX) holds a #2 Buy rating with a +0.59% ESP ahead of its November 2, 2026 earnings release, while Iovance Biotherapeutics (IOVA) has a #3 Hold rating with a +22.22% ESP before reporting on November 5, 2026. Both stocks show promise for positive earnings surprises based on the Zacks ESP methodology.

The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could outperform expectations: Align Technology (ALGN) with a +1.23% ESP ahead of October 28 earnings, and Iovance Biotherapeutics (IOVA) with a +22.22% ESP before November 5 earnings. Both stocks hold a Zacks Rank #3 (Hold) rating, and positive ESP combined with favorable rankings historically produce positive surprises 70% of the time.

Iovance Biotherapeutics raised its 2026 revenue outlook to $410-$420 million from $350-$370 million, driven by strong patient demand for its therapies Amtagvi and Proleukin. The stock surged 31.5% following the announcement. Amtagvi, the first FDA-approved TIL therapy for melanoma, generated $151 million in sales in H1 2026 with 54% year-over-year growth, and the company plans to expand authorized treatment centers from 100 to at least 110 by year-end.

Iovance Biotherapeutics shares surged 31.5% to $14.45 after the company raised its full-year 2026 revenue guidance to $410-$420 million from $350-$370 million. The stock is expected to report quarterly revenues of $106.85 million (up 58.4% year-over-year) with a loss of $0.12 per share. However, analysts note that without recent earnings estimate revisions, the stock's momentum may not sustain, and the company carries a Zacks Rank #3 (Hold) rating.

Iovance Biotherapeutics announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer effective September 30, 2026. Berkowitz brings extensive experience in global drug development and cell therapy from previous roles at Arvinas Pharmaceuticals and Bristol Myers Squibb, where he led clinical strategies resulting in FDA approvals for CAR-T cell therapies and other treatments. He will lead Iovance's TIL platform development across multiple solid tumor cancers.